Pharmaceuticals
MRK reported Q1 FY2026 revenue of $16.3B (+4.9% YoY), but swung to a net loss of -$4.24B driven by a massive $12.6B R&D expense surge (+247.7% YoY), likely reflecting a large in-process R&D charge from an acquisition, while operating cash flow improved significantly to $3.9B.
Key risk: Acquisition Integration and IPR&D Write-Off Risk
The apparent large acquisition driving the $12.6B R&D charge and $10.2B investing outflow creates significant integration risk. If the acquired pipeline assets fail in clinical trials or do not achieve commercial success, the company may face further impairments or write-downs on top of the already-recognized charge.
Other Pharmaceuticals companies